Immune Globulin Therapy
Customize your policy alerts
Sign up for blue cross blue shield - louisiana Policy 00170 alerts
Get alerted when Policy 00170 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and prior authorization for intravenous immune globulin (IVIG) and subcutaneous immune globulin (SCIG), including covered indications, clinical criteria, product step therapy, continuation requirements, and investigational uses. It applies to products administered or underwritten by Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc., subject to member contract benefits.
Severe anemia due to parvovirus B19 was added as an eligible hematologic indication for intravenous immune globulin therapy.
Kawasaki disease was deleted as an infectious-disease indication for intravenous immune globulin therapy.
Crohn disease, opsoclonus-myoclonus, birdshot retinopathy, epidermolysis bullosa acquisita, necrotizing fasciitis, and polyradiculoneuropathy other than CIDP were identified as investigational applications of intravenous immune globulin.
Prevention of sepsis in certain young populations was added as an indication tracked by the policy.
Hemolytic disease of the fetus and newborn, also called erythroblastosis fetalis, was added as an indication.
The coding section was revised to add ICD-10 diagnosis codes, remove ICD-9 procedure codes, and add HCPCS codes.
The policy removed prevention of infection in preterm and/or low-birth-weight neonates.
Alyglo and Yimmugo were added to the immune globulin therapy policy.
Carimune, Gamastan S/D, and Polygam S/D were removed from the policy as discontinued products.
The structure of the covered indications was updated.
A Primary Immunodeficiency Syndromes section was added to the Policy Guidelines.
A definition for severe refractory Myasthenia Gravis was added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.